Metagenomi Therapeutics, Inc. Financing Cash Flow
Metagenomi Therapeutics, Inc. (MGX) reported Financing Cash Flow of $40.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $67.00K.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$27.00K.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $74.00K.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$187.00K.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2025 was -$356.00K, a 100.42% decline from fiscal 2024.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $84.01M, a 8201.68% increase from fiscal 2023.
- Metagenomi Therapeutics, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $1.01M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $67.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $40.00K 10-Q · filed 2026-08-10 | $114.00K derived: sum of 3 quarters · filed 2026-08-10 | -$73.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$27.00K 10-Q · filed 2026-05-11 | $47.00K derived: sum of 2 quarters · filed 2026-05-11 | -$140.00K derived: sum of 3 quarters · filed 2026-05-11 | -$306.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$113.00K derived: sum of 2 quarters · filed 2026-03-05 | -$279.00K derived: sum of 3 quarters · filed 2026-08-10 | -$356.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | -$187.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$353.00K derived: sum of 2 quarters · filed 2026-08-10 | -$430.00K 10-Q · filed 2025-11-12 | -$430.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$166.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$243.00K 10-Q · filed 2026-08-10 | -$243.00K derived: sum of 3 quarters · filed 2026-08-10 | -$735.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$77.00K 10-Q · filed 2026-05-11 | -$77.00K derived: sum of 2 quarters · filed 2026-05-11 | -$569.00K derived: sum of 3 quarters · filed 2026-05-11 | -$2.60M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$492.00K derived: sum of 2 quarters · filed 2026-03-05 | -$2.52M derived: sum of 3 quarters · filed 2026-03-05 | $84.01M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$492.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$2.52M derived: sum of 2 quarters · filed 2025-11-12 | $84.01M 10-Q · filed 2025-11-12 | $82.68M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$2.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $84.50M 10-Q · filed 2025-08-12 | $83.17M derived: sum of 3 quarters · filed 2025-08-12 | $81.26M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $86.54M 10-Q · filed 2025-05-13 | $85.20M derived: sum of 2 quarters · filed 2025-05-13 | $83.29M derived: sum of 3 quarters · filed 2025-05-13 | $83.25M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$3.24M derived: sum of 2 quarters · filed 2025-03-17 | -$3.28M derived: sum of 3 quarters · filed 2025-03-17 | $1.01M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$1.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$1.95M derived: sum of 2 quarters · filed 2024-11-13 | $2.35M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$39.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $4.26M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $4.29M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |